ADIPOQ and Sepsis: Future studies should explore the potential synergistic benefits of combining adiponectin pathway modulators (e.g., AdipoR agonists, GLP-1RAs) with components of standard sepsis care, such as specific antimicrobial strategies, immunomodulatory agents currently under investigation, or targeted organ support techniques.